Aleniglipron - Gasherbrum Bio
Alternative Names: GSBR-1290Latest Information Update: 10 Sep 2026
At a glance
- Originator Gasherbrum Bio
- Developer Gasherbrum Bio; Structure Therapeutics
- Class Antihyperglycaemics; Antiparkinsonians; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity; Type 2 diabetes mellitus
- Preclinical Parkinson's disease
Most Recent Events
- 08 Sep 2026 Efficacy and adverse events data from the phase II ACCESS OLE trial in Obesity released by Structure Therapeutics
- 07 Aug 2026 Structure Therapeutics expects to initiate a clinical trial for Obesity (Combination-therapy) in Q4 2026 (PO)
- 17 Jul 2026 Phase-III clinical trials in Type 2 diabetes mellitus in USA (PO) (NCT07654374)